On October 5, 2023 KDx Diagnostics Inc., a leading innovator in non-invasive bladder cancer tests, reported the issuance of important patents in the US, EU, and South Korea relating to their joint work in developing new tests to aid in the treatment of bladder cancer (Press release, KDx Diagnostics, OCT 5, 2023, View Source [SID1234635697]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The issued patents cover technologies for analyzing Keratin 17 in urine to detect the presence or absence of bladder cancer. The patents reward the innovations of the joint team of scientists and researchers who developed the technology.

"These new patents complement our ongoing commercial efforts to provide non-invasive technologies for bladder cancer detection and demonstrate we’ve made groundbreaking advances," said Nam W. Kim, PhD, CEO and CTO at KDx, and coinventor of the patents. "We are focused on delivering cutting-edge solutions that address the needs of our customers and drive industry growth."

"As predicted by our research, Keratin 17 is an important marker for the detection of bladder cancer in patients," said Kenneth R. Shroyer, MD, PhD, The Marvin Kuschner Professor and Chair, Department of Pathology, Renaissance School of Medicine, Stony Brook Cancer Center, and coinventor of the patents. "We believe that the application of Keratin 17 in clinics will provide significant benefits to patients by providing a more accurate assessment of bladder cancer patients."